Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial
{{output}}
Background: Multiple sclerosis (MS), a chronic neurological disease, is typically managed with disease-modifying therapies (DMTs) to reduce relapse rates and slow disease progression. Some of these DMTs can cause infusion-related... ...
